Enniatin A was shown to impair Hsp90 function in cancer cells, provoke client degradation and immunogenic cell death, while avoiding upregulation of the heat-shock proteins Hsp70, Hsp40 and Hsp27, which offer a major advantage over classical N–terminal inhibitors. Here, HSP90AA1 is linked to cancer.